The cellular energy machinery — the mitochondria — is uniquely vulnerable to oxidative injury. Situated adjacent to the electron transport chain (ETC), which generates reactive oxygen species (ROS) as a byproduct of aerobic respiration, mitochondrial DNA (mtDNA) lacks protective histones and has limited repair capacity. The resulting oxidative stress produces two canonical damage products central to neurodegenerative biomarker research:

• 8-OHdG (8-hydroxy-2′-deoxyguanosine): The most abundant oxidative DNA lesion. ROS attack guanine at the C8 position, yielding 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG). Base-excision repair excises this adduct as free 8-OHdG, which enters urine, plasma/serum, and CSF.
• 8-OHG (8-hydroxyguanosine): The RNA analogue. Oxidation of ribonucleoside guanosine produces 8-OHG, which impairs ribosomal function and translation fidelity. Early literature sometimes conflated 8-OHdG (DNA) with 8-OHG (RNA); these must be distinguished. [1][28]
• mtDNA copy number (CN): Each cell contains 100–10,000 copies of the 16.6 kb circular mtDNA. Under bioenergetic stress, cells compensate by upregulating mtDNA replication (CN↑); chronic dysfunction causes depletion (CN↓). CN is measurable in blood, CSF, saliva, and post-mortem brain.
• Circulating cell-free mtDNA (cf-mtDNA): mtDNA released extracellularly via apoptosis, necrosis, or extracellular vesicles (EVs). Acts as a damage-associated molecular pattern (DAMP), activating innate immune receptors (TLR9, cGAS-STING, NLRP3). [25]

8-OHdG / 8-OHG Assays

mtDNA Quantification

Both 8-OHdG and mtDNA markers change substantially with normal aging, making age-matching and confounder control essential for disease biomarker research.

8-OHdG and Biological Aging

In a prospective cohort (n=198; ages 20–89), urinary 8-oxoG and 8-OHdG correlated positively with chronological age. A composite urinary panel including 8-OHdG and dityrosine (DTyr) predicted accelerated biological aging with >92% accuracy, positioning these markers as aging-rate indicators rather than purely disease-specific. [11] Critically, CSF 8-OHG did NOT correlate with age in healthy controls (r_s=−0.25, P=0.35), [1] giving CSF measurements an inherent advantage for disease specificity over urine/plasma.

mtDNA Copy Number and Aging

Blood mtDNA CN declines with normal aging across all 9 cohorts in the TOPMed meta-analysis (n=19,152). [12] This age-dependent decline can confound disease-specific findings if age-matching is inadequate.

Key Confounders to Control

CSF — RNA Oxidation (8-OHG)

OE audit CAUTION: The Abe 2002 paper specifically measured 8-OHG (RNA) using HPLC-ECD with a ribonucleoside-specific column, not 8-OHdG (DNA). This distinction is biologically significant: RNA oxidation impairs translational fidelity while DNA oxidation drives mutagenesis. Early citations mislabelled Abe 2002 as "CSF 8-OHdG". [1]

Serum 8-OHdG — Dose-Response Gradient

In a cross-sectional study (n=352: 131 AD / 121 MCI / 100 controls), serum 8-OHdG followed a Control < MCI < AD gradient (P<0.05 between groups) with negative correlations with both MoCA and MMSE. Serum 8-OHdG and SAA (serum amyloid A) were positively correlated, coupling oxidative and inflammatory pathways. [2]

Plasma 8-OHdG — MCI and Motoric Cognitive Risk

Plasma 8-OHdG is elevated in early AD. [5] In a large Chinese aging cohort (n=1,312 community elderly), plasma 8-OHdG was independently associated with motoric cognitive risk (MCR) after multivariable adjustment (OR 1.007 per unit, P=0.003). [6] MCR — defined as slow gait + subjective cognitive complaint — predicts dementia conversion.

Urinary 8-OHdG

Elevated in AD patients versus controls, inversely correlated with plasma paraoxonase-1 (PON1) activity (r=−0.536; P<0.01), coupling oxidative DNA damage with antioxidant enzyme depletion. [3] In AD patients with physical frailty, urinary 8-OHdG is elevated alongside IL-6 and TNF-α, suggesting shared oxidative-inflammatory mechanism. [4]

CSF 8-OHdG — Positive Stage Correlation

Disease-Stage Dissociation

In a larger study (n=44 PD, n=32 controls), both CSF 8-OHdG and 8-OHG were elevated in PD (P=0.02 and P=0.04 respectively). [8] Crucially, 8-OHdG elevation is specific to PD WITHOUT dementia (P=0.05), suggesting it marks early active neurodegeneration. By contrast, CSF 8-OHG is LOWER in PD with dementia versus controls (P=0.04) — possibly reflecting exhausted RNA production from already-dead neurons, or the transition from high-oxidative early PD to cell-loss-dominant late PD.

Urinary 8-OHdG — Disease Staging

In 72 PD patients (classic reference [9]), urinary 8-OHdG increased monotonically with Hoehn & Yahr (H&Y) stage (P<0.05 across stages). Crucially, the association was independent of levodopa dose, demonstrating that 8-OHdG elevation reflects intrinsic disease progression rather than dopaminergic therapy effect. This makes urinary 8-OHdG a potential staging biomarker that does not confound with treatment.

Blood 8-OHdG — 2026 Meta-Analysis

The most comprehensive analysis to date (Msigwa et al. 2026; 54 studies, n=722 PD + 3,277 controls, 2026) found blood-based 8-OHdG is moderately elevated in PD: Hedges' g=0.78 (95% CI 0.18–1.39; P=0.011). [10] F2-isoprostanes (lipid peroxidation) were NOT significantly elevated in PD (g=0.47; P=NS), distinguishing PD's oxidative damage profile (DNA-dominant) from T2DM (both elevated; 8-OHdG g=2.64). High I²>90% reflects assay and matrix heterogeneity, not contradictory findings.

Largest Meta-Analysis: Blood mtDNA CN and Cognition

PD: Tissue-Specific Reductions

In the largest mtDNA CN study in PD (n=363 peripheral blood + 151 substantia nigra pars compacta [SNpc] + 120 frontal cortex), both blood and SNpc mtDNA CN were significantly reduced in PD. [19] Frontal cortex CN was unchanged, demonstrating region-specificity: the reduction is not simply systemic degeneration but reflects nigral-specific mitochondrial pathology. The convergence of blood and SNpc reductions validates peripheral blood mtDNA CN as a proxy for brain mitochondrial dysfunction in PD.

Longitudinal Changes in AD Conversion

In an 8-year longitudinal study (n=75), individuals who converted to AD showed decreasing D-loop methylation and increasing mtDNA CN over time, while healthy controls showed progressive D-loop methylation increase. [16] This counterintuitive pattern (CN↑ in early converters) suggests compensatory upregulation of mtDNA replication in response to early mitochondrial stress — possibly preceding the eventual CN depletion seen in established AD.

Release Pathways

Extracellular mtDNA enters biofluids through multiple distinct mechanisms, each with different downstream signalling implications: [25][26]

• Apoptotic bodies: Fragmented mtDNA enclosed in membrane blebs during programmed cell death. Pro-inflammatory upon phagocytosis.
• Extracellular vesicles (EVs): Exosomes and microvesicles carrying mtDNA as cargo. EV-encapsulated cf-mtDNA may protect the mitochondrial genome during transport and represents a regulated release mechanism. CD9-positive EV cf-mtDNA is the key measurable fraction in CSF. [23]
• Necrotic release: Passive leakage from necrotic cells. Drives acute inflammatory signalling via DAMP pathway.
• Mitochondrial extrusion: Entire mitochondria can be ejected from stressed neurons — a recently described mechanism with pro-inflammatory consequences.

Innate Immune Activation by cf-mtDNA

Released cf-mtDNA activates innate immune receptors by virtue of its bacterial ancestry: CpG-rich, unmethylated mtDNA triggers TLR9 on microglia and peripheral immune cells, activating NF-κB and pro-inflammatory cytokine production. cGAS-STING senses cytosolic mtDNA and drives interferon responses. NLRP3 inflammasome is activated by mitochondrial ROS + mtDNA interaction, producing IL-1β and IL-18 — which promote neuroinflammation in AD and PD. [25]

This neuro-immune axis means that cf-mtDNA is not merely a passive injury marker but an active mediator of neuroinflammation. Lowering cf-mtDNA or blocking TLR9 may reduce downstream neuroinflammation — a therapeutic implication.

CSF cf-mtDNA in AD — Contradictory Findings

Slow-progressive AD (spAD, Podlesniy 2020): CSF cf-mtDNA was 44% lower than controls in spAD (69% lower in biomarker-selected cohort). Rapid-progressive AD (rpAD) showed no significant difference. The cf-mtDNA/p-tau ratio achieved sensitivity 93%, specificity 94% for spAD in a biomarker-selected cohort (n=95 total: 30 spAD, 16 rpAD, 49 controls). [15] This is among the highest diagnostic performances reported for any novel CSF biomarker, but requires external validation in independent cohorts.

Cervera-Carles 2017: In 124 AD and 140 controls, CSF mtDNA was elevated in AD (AUC=0.715), but with considerable overlap — not clinically useful as a standalone marker. The discrepancy with Podlesniy likely reflects different patient populations (AD continuum vs confirmed spAD) and different pre-analytical protocols. [14]

Plasma ccf-mtDNA in MCI

In 332 older adults with MCI ± remitted major depressive disorder (rMDD), plasma ccf-mtDNA was elevated specifically in APOE-ε4 carriers with MCI (P=0.05). [17] This gene-environment interaction suggests that mtDNA stress is amplified in genetically at-risk individuals, and that APOE genotype should be reported and stratified in future MCI biomarker studies.

Salivary mtDNA CN in Preclinical AD

In cognitively normal older adults, salivary mtDNA CN was positively correlated with cortical amyloid-β (Aβ) burden by PET and with plasma pTau-181, but NOT with NfL or GFAP. [18] This specificity for amyloid/tau pathology rather than general neurodegeneration markers suggests that salivary mtDNA tracks early Aβ accumulation — potentially enabling non-invasive preclinical screening.

Immune-Mitochondrial Crosstalk in AD

In AD patients, mtDNA indicators (CN and cf-mtDNA) correlate with mitogen-stimulated cytokine production profiles, coupling mitochondrial stress to peripheral immune dysregulation. [30] A pilot study (n=20/group) found sex-stratified effects: CSF SOD2 (mitochondrial antioxidant) is elevated specifically in males with MCI; plasma DNase I and MMP-2 are elevated in AD, suggesting active cf-mtDNA clearance failure. [27]

iPD vs LRRK2-PD: Mechanistically Opposite

Deletion ratio: iPD has a high cf-mtDNA deletion ratio (large deletions in mt64-ND1 and mt96-ND5 regions) whereas LRRK2-PD has no detectable deletions. [21] The deletion ratio may be more informative than absolute CN for distinguishing PD subtypes.

Nutritional confounding (Mizutani 2025): In 44 PD / 43 controls, lower CSF mt64-ND1 (P=0.002) and mt96-ND5 (P=0.001) confirmed iPD's cf-mtDNA depletion. Critically, body composition and serum albumin were independently associated with CSF cf-mtDNA levels — nutritional status is a major confounder for CSF cf-mtDNA that future studies must control. [22]

Post-Mortem Ventricular CSF

In post-mortem ventricular CSF from neurodegenerative disease patients, cf-mtDNA was reduced specifically in PD but not in AD, DLB, or MSA — suggesting PD-specific mitochondrial biology. [24] A counterintuitive observation: within PD patients, higher cf-mtDNA levels correlated with more severe clinical presentation, suggesting that severely affected neurons release more cf-mtDNA before eventual depletion. This non-linear relationship complicates interpretation of cross-sectional findings.

iRBD — Prodromal Lewy Body Disease

In a prospective study of 71 participants (17 non-converters, 34 converters to PD/DLB, 20 controls), iRBD patients — regardless of phenoconversion — had more cf-mtDNA deletions in CSF and reduced CD9-positive EV-encapsulated cf-mtDNA CN. [23] Paradoxically, serum cf-mtDNA was INCREASED in iRBD converters, opposite to CSF direction. This blood/CSF discordance likely reflects different release mechanisms: EV-mediated release to CSF is reduced (EV biogenesis impaired), while passive leakage into blood increases due to cell membrane damage.

The key implication: mtDNA structural damage (deletions) appears in iRBD patients before phenoconversion, positioning cf-mtDNA deletions as a prodromal Lewy body disease marker — potentially useful for identifying iRBD patients at highest conversion risk.

The mitochondrial displacement loop (D-Loop) is the non-coding regulatory region governing mtDNA replication and transcription. Unlike nuclear DNA methylation, mtDNA D-Loop methylation is regulated independently and responds to metabolic and oxidative stress.

D-Loop Methylation in AD

In the 8-year longitudinal study (n=75), AD converters showed progressive D-Loop methylation decrease paired with mtDNA CN increase, while healthy controls showed increasing D-Loop methylation over time. [16] This suggests that D-Loop hypomethylation may be an early epigenetic signal of mitochondrial dysregulation, preceding clinical AD by months to years. The opposing trajectories of converters vs controls offer a potential dynamic biomarker: rate of D-Loop methylation change over serial blood draws may predict conversion risk.

D-Loop Methylation in PD

In PD patients' peripheral blood DNA, D-Loop region methylation was altered, with specific CpG sites showing differential methylation compared to controls. [29] Importantly, the direction of methylation change differed by CpG site and disease stage, suggesting that D-Loop methylation is a complex, site-specific biomarker rather than a single uniform change. The functional consequence of altered D-Loop methylation in PD likely involves dysregulated mtDNA transcription, contributing to reduced mtDNA CN.

mtDNA Deletions in PD and iRBD

Large-scale mtDNA deletions (detected by ddPCR targeting ND1 and ND5 regions) are highly elevated in iPD CSF [21] and precede phenoconversion in iRBD. [23] Unlike CN changes (which can reflect either compensatory increases or depletion), deletion ratios directly reflect accumulated oxidative damage to the mitochondrial genome — cumulative errors from long-term ROS exposure that cannot be repaired by base-excision repair.

Peripheral blood mononuclear cells (PBMCs) — monocytes, T cells, NK cells — carry their own mitochondria and serve as a window into systemic mitochondrial health. In neurodegenerative diseases, PBMC mitochondrial dysfunction parallels brain pathology.

PBMC Mitochondrial Dysfunction in AD

In AD patients, mtDNA indicators in PBMCs (including CN and methylation status) correlate significantly with mitogen-stimulated cytokine production profiles (IL-2, IL-4, IL-6, TNF-α, IFN-γ). [30] This coupling of mitochondrial stress to immunological dysfunction suggests that peripheral immune cells in AD are metabolically compromised, with mitochondrial dysfunction impairing their ability to mount appropriate immune responses. Clinically, this may explain the increased susceptibility of AD patients to infections and the immunosenescence phenotype observed in dementia.

ccf-mtDNA as Neuro-Immune Mediator

ccf-mtDNA acts as a DAMP signalling molecule between the brain and peripheral immune system. [25] In the CNS, damaged neurons release mtDNA-containing EVs into CSF; these can cross the blood-brain barrier or drain via glymphatic/lymphatic routes, activating peripheral TLR9+ immune cells. This bidirectional signalling means that peripheral immune activation (reflected in PBMC cytokine profiles) is mechanistically linked to brain mtDNA release.

Sex-Stratified Effects

In a pilot study of AD and MCI patients, CSF superoxide dismutase 2 (SOD2) — the primary mitochondrial antioxidant enzyme — was elevated specifically in male MCI patients, not females. [27] Plasma DNase I (responsible for cf-mtDNA degradation) and MMP-2 were elevated in AD patients, suggesting that the failure of cf-mtDNA clearance (rather than just increased production) contributes to the sustained DAMP signalling in AD. These sex differences underscore the need for sex-stratified analysis in future biomarker studies.

Coenzyme Q-10 (CoQ-10, ubiquinol/ubiquinone) is an essential electron carrier in the mitochondrial ETC and a lipid-soluble antioxidant. Its oxidation ratio (%oxidized CoQ-10 = ubiquinone / total CoQ-10) reflects the redox burden on the ETC.

CSF CoQ-10 and 8-OHdG in PD

In 20 PD patients and 20 controls (Isobe 2010), both CSF 8-OHdG and %oxidized CoQ-10 were significantly elevated in PD. [7] The two markers were positively correlated (r_s=0.56, P<0.05), directly demonstrating the mechanistic link: ETC dysfunction (measured by CoQ-10 oxidation) → increased mitochondrial ROS → DNA oxidative damage (8-OHdG). This correlation provides biochemical evidence that CSF 8-OHdG in PD reflects mitochondrial rather than purely cytoplasmic or inflammatory oxidative stress.

Clinical Implications of CoQ-10 Depletion

Brain CoQ-10 levels are reduced in PD substantia nigra by approximately 35% (from post-mortem studies), and plasma CoQ-10 is reduced by 25–40% in PD patients. The parallel elevation of CSF 8-OHdG and %oxidized CoQ-10 in living PD patients supports CoQ-10 supplementation trials as a neuroprotective strategy — though clinical trials to date (NINDS NET-PD; QE2 trial) have not shown efficacy at doses up to 1,200–2,400 mg/day, possibly because oral CoQ-10 has poor CNS bioavailability.

The following framework integrates all biomarkers reviewed into a unified model of mitochondrial oxidative stress in neurodegeneration:

No formal head-to-head comparison of 8-OHdG or mtDNA markers against established biomarkers (p-tau217, NfL, Aβ42/40, α-synuclein) exists. However, existing data suggest complementarity:

Why Combination Matters

8-OHdG reflects downstream oxidative DNA damage (end-product); mtDNA CN and cf-mtDNA reflect upstream mitochondrial biogenesis and structural integrity; D-Loop methylation adds epigenetic regulation. These markers are mechanistically complementary and may capture different stages of the same pathological cascade, increasing sensitivity for early detection when combined with established AD/PD biomarkers.

Standardisation — Most Urgent Priority

The field cannot progress without assay standardisation. Current barriers: [26]

• No consensus on pre-analytical protocols for 8-OHdG (HPLC vs ELISA; timing of sample processing)
• No standardised reference mtDNA region or normalisation gene for qPCR-based CN measurement
• No agreed-upon ddPCR protocol for deletion ratio quantification
• Absolute values across studies are incomparable; only directional findings can be pooled

Head-to-Head Biomarker Comparisons

Not a single study has compared 8-OHdG or cf-mtDNA directly against p-tau217, NfL, Aβ42/40, or α-synuclein seed amplification in the same cohort using a formal biomarker comparison design (DeLong test for AUC comparison). This is the most critical evidence gap for translating these markers to clinical practice.

Longitudinal Studies

Cross-sectional studies dominate the field. Key needed longitudinal designs: (1) community cohorts tracking urine/plasma 8-OHdG from cognitively normal through MCI to dementia; (2) prodromal PD cohorts (iRBD, REM sleep behaviour disorder) with serial CSF cf-mtDNA deletion assays; (3) AD conversion studies pairing D-Loop methylation with Aβ PET.

Therapeutic Implications

If cf-mtDNA-driven TLR9/NLRP3 neuroinflammation is a causal mechanism (not yet proven), therapeutic targets include: TLR9 antagonists (e.g., IMO-8400), NLRP3 inhibitors (e.g., MCC950), DNase I (to clear cf-mtDNA), and CoQ-10 analogues with better CNS penetration (e.g., MitoQ). Antioxidant intervention trials (Vitamin E, CoQ-10) have failed in AD/PD — likely because interventions were too late or systemic antioxidants did not reach mitochondria at sufficient concentrations.

Technical Advances

• Long-read sequencing (ONT/PacBio): Complete mtDNA sequencing in a single read — enables heteroplasmy mapping, full deletion profiling
• Single-EV analysis: Measuring mtDNA content per individual EV subpopulation (CD9+, CD63+ etc.) to understand compartment-specific release
• Plasma proteomics + mtDNA CN multi-omic integration: Combining cf-mtDNA with proteomics (SOD2, DNase I, MMP-2) for mechanistic profiling
• Salivary and urinary non-invasive panels: Large-scale validation for population screening (8-OHdG urine + salivary mtDNA CN)

1. Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res. 2002;70(3):447–50. PMID 12391605
2. Cao X, Chen P. Changes in Serum Amyloid A (SAA) and 8-OHdG in Patients with Senile Early Cognitive Impairment. Med Sci Monit. 2020;26:e919586. PMID 32006457
3. Zengi O, Karakas A, Ergun U, Senes M, Inan L, Yucel D. Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer's disease. Clin Chem Lab Med. 2012;50(3):529–34. PMID 22098435
4. Namioka N, Hanyu H, Hirose D, et al. Oxidative stress and inflammation are associated with physical frailty in patients with Alzheimer's disease. Geriatr Gerontol Int. 2017;17(6):913–8. PMID 27296166Local Drive
5. Peña-Bautista C, Tirle T, López-Nogueroles M, et al. Oxidative Damage of DNA as Early Marker of Alzheimer's Disease. Int J Mol Sci. 2019;20(24):6136. PMID 31817451
6. Dai Q, Ma Y, Liu C, et al. Association of 8-hydroxy-2′-deoxyguanosine with motoric cognitive risk in elderly Chinese people. BMC Geriatr. 2024;24(1):331. PMID 38605326
7. Isobe C, Abe T, Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-OHdG in the CSF of patients with living Parkinson's disease. Neurosci Lett. 2010;469(1):159–63. PMID 19944739
8. Gmitterová K, Gawinecka J, Heinemann U, Valkovič P, Zerr I. DNA versus RNA oxidation in Parkinson's disease: Which is more important? Neurosci Lett. 2018;662:22–28. PMID 28963060
9. Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology. 2005;64(6):1081–3. PMID 15781836
10. Msigwa SS, Mkwambe MC, Yu QY, et al. Comparative evaluation of oxidative stress biomarkers F2-isoprostanes and 8-OHdG in Parkinson's disease and Type 2 Diabetes Mellitus: a systematic review and meta-analysis. Ann Med. 2026;58(1):2654251. PMID 42003321
11. Mukli P, Wu DH, Csipo T, et al. Urinary Biomarkers of Oxidative Stress in Aging: Implications for Prediction of Accelerated Biological Age. Oxid Med Cell Longev. 2022:6110226. PMID 35571254
12. Zhang Y, Liu X, Wiggins KL, et al. Association of Mitochondrial DNA Copy Number With Brain MRI Markers and Cognitive Function: A Meta-analysis of Community-Based Cohorts. Neurology. 2023;100(18):e1930–43. PMID 36927883Local Drive
13. Podlesniy P, Llorens F, Golanska E, et al. Mitochondrial DNA differentiates Alzheimer's disease from Creutzfeldt-Jakob disease. Alzheimers Dement. 2016;12(5):546–55. PMID 26806388
14. Cervera-Carles L, Alcolea D, Estanga A, et al. Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. Neurobiol Aging. 2017;53:192.e1–e4. PMID 28089353Local Drive
15. Podlesniy P, Llorens F, Puigròs M, et al. Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer's Disease. Int J Mol Sci. 2020;21(17):6298. PMID 32878083Local Drive
16. Rizzo B, Rossi M, Ferrari RR, et al. Longitudinal Analysis of Mitochondrial D-Loop Methylation and Copy Number in Peripheral Blood: Epigenetic Signatures of Alzheimer's Disease Progression and Aging. Int J Mol Sci. 2026;27(3):1477. PMID 41683898
17. Choi J, Beroncal EL, Chernega T, et al. Exploring mitochondrial blood-based and genetic markers in older adults with mild cognitive impairment and remitted major depressive disorder. Transl Psychiatry. 2024;14(1):457. PMID 39468012
18. Cantero JL, Atienza M, Podlesniy P, Puigròs M, Trullas R. Salivary mitochondrial DNA is associated with biomarkers of Alzheimer's disease in cognitively normal older adults. Transl Psychiatry. 2025;15(1):355. PMID 41052979
19. Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease. Neurobiol Aging. 2016;38:216.e7–e10. PMID 26639155
20. Podlesniy P, Vilas D, Taylor P, Shaw LM, Tolosa E, Trullas R. Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease. Neurobiol Dis. 2016;94:10–17. PMID 27260835
21. Puigròs M, Calderon A, Pérez-Soriano A, et al. Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease. Neurobiol Dis. 2022;174:105885. PMID 36208866
22. Mizutani Y, Nakai T, Maeda Y, et al. CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease. Ann Clin Transl Neurol. 2025;12(12):2410–21. PMID 40891077
23. Puigròs M, Calderon A, Martín-Ruiz D, et al. Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder. EBioMedicine. 2024;102:105065. PMID 38502973
24. Lowes H, Kurzawa-Akanbi M, Pyle A, Hudson G. Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease. Sci Rep. 2020;10(1):15253. PMID 32943697
25. Gambardella S, Limanaqi F, Ferese R, et al. ccf-mtDNA as a Potential Link Between the Brain and Immune System in Neuro-Immunological Disorders. Front Immunol. 2019;10:1064. PMID 31143191Local Drive
26. Risi B, Imarisio A, Cuconato G, et al. Mitochondrial DNA (mtDNA) as fluid biomarker in neurodegenerative disorders: A systematic review. Eur J Neurol. 2025;32(1):e70014. PMID 39831374Local Drive
27. Di Lorenzo R, Zecca C, Chimienti G, et al. Reliable New Biomarkers of Mitochondrial Oxidative Stress and Neuroinflammation in CSF and Plasma from Alzheimer's Disease Patients: A Pilot Study. Int J Mol Sci. 2025;26(16):7792. PMID 40869114
28. Cioffi F, Adam RHI, Bansal R, Bhatt D. A Review of Oxidative Stress Products and Related Genes in Early Alzheimer's Disease. J Alzheimers Dis. 2021;83(3):977–1000. PMID 34420962
29. Stoccoro A, Smith AR, Baldacci F, et al. Mitochondrial D-Loop Region Methylation and Copy Number in Peripheral Blood DNA of Parkinson's Disease Patients. Genes (Basel). 2021;12(5):720. PMID 34065874
30. Huang J, Song Z, Wei B, et al. Immunological evaluation of patients with Alzheimer's disease based on mitogen-stimulated cytokine productions and mitochondrial DNA indicators. BMC Psychiatry. 2023;23(1):160. PMID 36890488Local Drive